Select Publications
Conference Papers
2006, 'A low sodium, high potassium salt substitute substantially lowers blood pressure levels among high-risk individuals in rural northern China - The China Salt Substitute Study', in JOURNAL OF HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, SPAIN, Madrid, pp. S150 - S151, presented at 16th European Meeting on Hypertension, SPAIN, Madrid, 12 June 2006 - 15 June 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240281001022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2004, 'Lacunar stroke in PROGRESS study', in EUROPEAN JOURNAL OF NEUROLOGY, BLACKWELL PUBLISHING, pp. 29 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000202992100093&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2004, 'Effects of perindopril-based blood pressure lowering on the risks of recurrent stroke in patients with and without diabetes: The PROGRESS Trial', in STROKE, LIPPINCOTT WILLIAMS & WILKINS, CANADA, Vancouver, pp. E285 - E285, presented at 5th World Stroke Congress, CANADA, Vancouver, 23 June 2004 - 26 June 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000221676600782&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2003, 'Fat distribution is strongly associated with plasma glucose levels and diabetes in Thai adults - The InterASIA study', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, HAWAII, HONOLULU, pp. E132 - E132, presented at Asia Pacific Scientific Forum on New Discoveries in Cardiovascular Disease and Stroke, HAWAII, HONOLULU, 08 June 2003 - 10 June 2003, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000183014500028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2002, 'Managing the global burden of cardiovascular disease', in European Heart Journal, Supplement, http://dx.doi.org/10.1016/S1520-765X(02)90022-2
,2001, 'Blood pressure lowering in diabetes: A brief review of the current evidence and description of a new trial', in Clinical and Experimental Pharmacology and Physiology, pp. 1108 - 1111, http://dx.doi.org/10.1046/j.1440-1681.2001.03581.x
,2001, 'Cardiovascular risk factors in a cohort of 3,499 Thais from 1985-1997', in EUROPEAN HEART JOURNAL, W B SAUNDERS CO LTD, pp. 714 - 714, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000170988302735&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2000, 'Blood pressure and stroke risk in Asia Pacific populations', in JOURNAL OF HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, pp. S25 - S25, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000090000800127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1999, '1999 world health organization-international society of hypertension guidelines for the management of hypertension', in Journal of Hypertension, pp. 151 - 183, http://dx.doi.org/10.3109/10641969909061028
,1999, '7th WHO-ISH Meeting on Hypertension, Fukuoka, Japan, 29 September to October, 1998: 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension', in Journal of Hypertension, pp. 151 - 183
,1999, 'An overview of 37 randomised trials of blood pressure lowering agents among 270,000 individuals', in Clinical and Experimental Hypertension, pp. 517 - 529, http://dx.doi.org/10.3109/10641969909060985
,1998, '1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension', in CLINICAL AND EXPERIMENTAL HYPERTENSION, TAYLOR & FRANCIS INC, JAPAN, FUKUOKA, pp. 1009 - 1060, presented at International Expert Meeting on Hypertension, JAPAN, FUKUOKA, 28 September 1998 - 01 October 1998, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000081512600048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1998, 'PROGRESS: Perindopril protection against recurrent stroke study: Status in March 1997', in Journal of Human Hypertension, pp. 627 - 629, http://dx.doi.org/10.1038/sj.jhh.1000677
,1997, 'Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease', in Clinical and Experimental Hypertension, pp. 843 - 855, http://dx.doi.org/10.3109/10641969709083190
,1996, 'PROGRESS - perindopril protection against recurrent stroke study: Status in July 1996', in Journal of Hypertension, Supplement
,1995, 'Blood pressure lowering for the primary and secondary prevention of coronary and cerebrovascular disease', in Schweizerische Medizinische Wochenschrift, pp. 2479 - 2486
,Conference Posters
2022, 'POS-392 CANAGLIFLOZIN TREATMENT IMPACTS COLLAGEN TYPE III DEGRADATION AND FORMATION IN THE CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT STUDY (CANVAS)', Vol. 7, pp. S177 - S177, http://dx.doi.org/10.1016/j.ekir.2022.01.414
,2020, '1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)', ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-1130-p
,2020, 'The Redox Balance Predicts Both Cardiovascular (CV) and Renal Outcomes in CANVAS', ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-139-LB
,2020, 'EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION', Chicago, IL, Vol. 75, pp. 221 - 221, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), Chicago, IL, 28 March 2020 - 30 March 2020, http://dx.doi.org/10.1016/S0735-1097(20)30848-2
,Conference Presentations
2022, '19-OR: KidneyIntelX Association with Clinical Outcomes in Diabetic Kidney Disease', http://dx.doi.org/10.2337/db22-19-or
,2020, 'Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE', presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-26-OR
,Conference Abstracts
2022, 'Substituting the world's salt supply', in Journal of Hypertension, Lippincott, Williams & Wilkins, JAPAN, Kyoto, Vol. 41, pp. E119 - E119, presented at 29th Scientific Meeting of the International Society of Hypertension (ISH), JAPAN, Kyoto, 12 October 2022 - 16 October 2022, http://dx.doi.org/10.1097/01.hjh.0000913896.40673.c0
,2022, 'CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL', in NEPHROLOGY, WILEY, Vol. 27, pp. 15 - 15, http://dx.doi.org/10.26190/unsworks/28407
,2022, 'Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA(1c) and predicted risk of kidney failure', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 65, pp. S278 - S278, presented at 58th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 19 September 2022 - 23 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000841795900548&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 65, pp. S132 - S132, presented at 58th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 19 September 2022 - 23 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000841795900252&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'The effect of salt substitution on headache: a cluster-randomized controlled trial', in CEPHALALGIA, SAGE PUBLICATIONS LTD, Vol. 42, pp. 61 - 62, http://dx.doi.org/10.26190/unsworks/28462
,2022, 'EFFECTS OF SALT SUBSTITUTES ON BLOOD PRESSURE AND CLINICAL OUTCOMES IN DIFFERENT POPULATION GROUPS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, Vol. 79, pp. 1454 - 1454, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000781026601553&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Estimated Benefits And Risks Of Lowering Sodium Through Potassium-enriched Salt Substitution In India: A Modeling Study', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, Vol. 145, http://dx.doi.org/10.1161/circ.145.suppl_1.019
,2021, 'Heart failure therapies for the prevention of HER2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 119 - 119, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'The Impact of Australasian Voluntary Front of Pack Nutrition Labelling on Packaged Food Reformulation', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, Vol. 50, pp. 21 - 21, http://dx.doi.org/10.1093/ije/dyab168.050
,2021, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial', in Diabetes, Obesity and Metabolism, Vol. 23, pp. 1652 - 1659, http://dx.doi.org/10.1111/dom.14386
,2021, 'HOW MANY ADDITIONAL PHYSICIANS ARE NEEDED FOR HYPERTENSION TREATMENT IN INDIA?', in Journal of Hypertension, Wolters Kluwer, Vol. 39, pp. e85, http://dx.doi.org/10.1097/01.hjh.0000745236.87471.17
,2021, 'Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus', in Metabolism, Elsevier, Vol. 116, pp. 154509, http://dx.doi.org/10.1016/j.metabol.2020.154509
,2020, 'Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S269 - S269, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000565776600560&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S61 - S62, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, http://dx.doi.org/10.26190/unsworks/27933
,2020, 'Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 41, pp. 1175 - 1175, presented at European-Society-of-Cardiology (ESC) Congress, ELECTR NETWORK, 29 August 2020 - 01 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606106301178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial', in DIABETES, AMER DIABETES ASSOC, ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-1120-P
,2020, 'Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial', in DIABETES, AMER DIABETES ASSOC, ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-1098-P
,2020, 'CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1336 - 1336, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000562392101381&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1342 - 1342, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000562392101387&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1351 - 1351, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, http://dx.doi.org/10.1093/ndt/gfaa142|iii1351
,2020, 'Contribution of Major Food Companies and Their Products to Household Dietary Sodium Purchases in Australia', in Current Developments in Nutrition, Oxford University Press (OUP), presented at American Society of Nutrition 2020, http://dx.doi.org/10.1093/cdn/nzaa067_017
,2020, 'CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 1018 - 1018, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979101006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 1852 - 1852, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979101839&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 215 - 215, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979100211&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S343 - S343, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S341 - S342, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S340 - S341, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'DIFFERENT EGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, HUNGARY, Budapest, Vol. 34, pp. 206 - 206, presented at 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease, HUNGARY, Budapest, 13 June 2019 - 16 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000495412900569&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,